Candriam SCA’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Candriam SCA’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-502,177	Closed	-$3.06M	–	837
2020 Q2	$3.06M	Buy	502,177 +502,171	+8,369,517%	+$2.07M	0.03%	420
2020 Q1	$0	Buy	+6	New	+$25	﹤0.01%	797
2018 Q3	–	Sell	-80,000	Closed	-$1.26M	–	856
2018 Q2	$1.26M	Hold	80,000	–	–	0.02%	564
2018 Q1	$1.37M	Hold	80,000	–	–	0.02%	539
2017 Q4	$1.75M	Buy	80,000 +30,000	+60%	+$965K	0.03%	481
2017 Q3	$2.05M	Sell	50,000 -9,000	-15%	-$283K	0.04%	449
2017 Q2	$1.78M	Buy	59,000 +27,000	+84%	+$843K	0.03%	486
2017 Q1	$1.16M	Hold	32,000	–	–	0.02%	541
2016 Q4	$1.6M	Buy	32,000 +8,000	+33%	+$420K	0.04%	410
2016 Q3	$1.26M	Sell	24,000 -3,000	-11%	-$143K	0.03%	449
2016 Q2	$1.12M	Sell	27,000 -9,000	-25%	-$391K	0.03%	414
2016 Q1	$1.46M	Sell	36,000 -75,300	-68%	-$2.59M	0.04%	369
2015 Q4	$4.62M	Buy	111,300 +14,000	+14%	+$469K	0.12%	188
2015 Q3	$1.5M	Buy	+97,300	New	+$2.09M	0.04%	382

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Candriam SCA's FPRX Position: Q3 2020 in Review

Candriam SCA sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2020, closing a stake of 502,177 shares — an estimated $3.06M sold.

Candriam SCA first reported a position in FPRX in Q3 2015 and held it in 14 quarters. The position peaked at $4.62M in Q4 2015. 94 funds tracked by Wall St. Rank hold FPRX as of Q3 2020.

Candriam SCA reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
Candriam SCA sold 502,177 Five Prime Therapeutics, Inc. shares in Q3 2020, an estimated $3.06M.
Candriam SCA first reported a position in Five Prime Therapeutics, Inc. in Q3 2015 and held it in 14 quarters.
Candriam SCA's Five Prime Therapeutics, Inc. position peaked at $4.62M in Q4 2015.
94 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2020.

Based on Candriam SCA's 13F filing for Q3 2020, filed 19 Oct 2020.